Table of Content

1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: REGIONAL SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 MAJOR MARKET STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
    1.7 RECESSION IMPACT 
2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from industry experts
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 5 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET
                                FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: BAXTER INTERNATIONAL INC.
          FIGURE 9 REVENUE SHARE ANALYSIS FOR TOP PLAYERS
          FIGURE 10 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
          FIGURE 11 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY CONSUMABLES
          FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN MARKET (2023–2028)
          FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 14 TOP-DOWN APPROACH
    2.3 DATA TRIANGULATION 
          FIGURE 15 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS 
    2.5 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.6 LIMITATIONS 
    2.7 METHODOLOGY-RELATED LIMITATIONS 
    2.8 RECESSION IMPACT 
3 EXECUTIVE SUMMARY (Page No. - 50)
    FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 17 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY MODALITY, 2023 VS. 2028 (USD MILLION)
    FIGURE 18 MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION)
    FIGURE 19 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 20 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW 
          FIGURE 21 RISING PREVALENCE OF ACUTE KIDNEY INJURY AND GROWING AWARENESS OF CRRT TO DRIVE MARKET
    4.2 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT AND COUNTRY (2022) 
          FIGURE 22 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 REGIONAL MIX: MARKET (2021–2028) 
          FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 MARKET: EMERGING VS. DEVELOPED MARKETS 
          FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 58)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of acute kidney injury (AKI)
                                FIGURE 27 GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY, 2010 VS. 2015 VS. 2020
                                TABLE 2 NUMBER OF PEOPLE AGED 65 OR OVER, BY REGION, 2019 VS. 2050
                    5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
                                FIGURE 28 IMPACT OF ICU-ACQUIRED AKI IN US
                    5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
                    5.2.1.4 Technological advancements and new product launches
                    5.2.1.5 Growing prevalence of diabetes and hypertension
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulatory guidelines in North America
                    5.2.2.2 High procedural cost of CRRT
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets in Asia Pacific and RoW
                    5.2.3.2 Increasing applications of CRRT
                               5.2.3.2.1 Evolution of CRRT from simple renal replacement treatment to multi-organ support therapy
                               5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
                    5.2.3.3 Ongoing research to establish safety and efficacy profile of CRRT
                    5.2.3.4 Development of CRRT systems for pediatric patients
                               5.2.3.4.1 The CARPEDIEM Project
                    5.2.3.5 Untapped growth opportunities in North America
           5.2.4 CHALLENGES
                    5.2.4.1 High complexity of CRRT
                    5.2.4.2 Lack of standard treatment guidelines in developing nations
                    5.2.4.3 Shortage of trained ICU professionals in developing nations
                    5.2.4.4 Poor reimbursement scenario in developing countries
                    5.2.4.5 Lack of awareness about benefits of CRRT
    5.3 REGULATORY ANALYSIS 
           5.3.1 NORTH AMERICA
           5.3.2 EUROPE
           5.3.3 ASIA PACIFIC
                    5.3.3.1 India
                    5.3.3.2 China
                    5.3.3.3 Japan
                    5.3.3.4 South Korea
           5.3.4 REST OF THE WORLD (ROW)
                    5.3.4.1 Brazil
                    5.3.4.2 Argentina
    5.4 REIMBURSEMENT SCENARIO 
           5.4.1 NORTH AMERICA
           5.4.2 EUROPE
           5.4.3 ASIA PACIFIC
                    5.4.3.1 Japan
           5.4.4 REST OF THE WORLD (ROW)
                    5.4.4.1 Brazil
                    5.4.4.2 Central America and the Caribbean
    5.5 KEY CONFERENCES & EVENTS 
          TABLE 3 KEY CONFERENCES & EVENTS, 2023
    5.6 PATENT ANALYSIS 
           5.6.1 PATENT PUBLICATION TRENDS FOR CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
                    FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2013–AUGUST 2023)
           5.6.2 INSIGHTS ON JURISDICTION AND TOP APPLICANT ANALYSIS
                    FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
                    FIGURE 31 TOP 10 APPLICANT COUNTRIES/REGIONS FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
                    TABLE 4 MARKET: LIST OF MAJOR PATENTS
    5.7 TRADE ANALYSIS 
    5.8 TECHNOLOGY ANALYSIS 
           5.8.1 MINIMALLY INVASIVE CRRT
           5.8.2 CRRT IN COMBINATION WITH OTHER THERAPIES
    5.9 ECOSYSTEM ANALYSIS 
    5.10 VALUE CHAIN ANALYSIS 
           FIGURE 32 VALUE CHAIN OF MARKET
    5.11 PRICING TREND ANALYSIS 
           TABLE 5 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 6 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 INTENSITY OF COMPETITIVE RIVALRY
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MARKET
                     TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MARKET
           5.13.2 BUYING CRITERIA
                     FIGURE 34 KEY BUYING CRITERIA FOR MARKET
                     TABLE 8 KEY BUYING CRITERIA FOR MARKET
    5.14 ARTIFICIAL INTELLIGENCE INTEGRATION IN CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS 
    5.15 UNMET NEED & END-USER EXPECTATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS 
6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT (Page No. - 85)
    6.1 INTRODUCTION 
          TABLE 9 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 DIALYSATE & REPLACEMENT FLUIDS 
           6.2.1 RISING DEMAND FOR DIALYSATE TO DRIVE MARKET
                    TABLE 10 DIALYSATE & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 DISPOSABLES 
          TABLE 11 DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 12 DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.1 HEMOFILTERS
                    6.3.1.1 Widely adopted during CRRT procedures for treatment of AKI
                                 TABLE 13 HEMOFILTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 BLOODLINE SETS & TUBES
                    6.3.2.1 Development of blood tubing with special coding to prevent clotting to offer growth opportunities
                                 TABLE 14 BLOODLINE SETS & TUBES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 OTHER DISPOSABLES
                    TABLE 15 OTHER DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 CRRT SYSTEMS 
           6.4.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED, EASY-TO-USE SYSTEMS TO BOOST MARKET GROWTH
                    TABLE 16 CRRT SYSTEMS MARKET BY COUNTRY, 2021–2028 (USD MILLION)
7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY (Page No. - 94)
    7.1 INTRODUCTION 
          TABLE 17 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY MODALITY, 2021–2028 (USD MILLION)
    7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION 
           7.2.1 WIDESPREAD ADOPTION IN TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET
                    TABLE 18 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION 
           7.3.1 USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
                    TABLE 19 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS 
           7.4.1 MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES COMPARED TO OTHER CRRT MODALITIES
                    TABLE 20 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 SLOW CONTINUOUS ULTRAFILTRATION 
           7.5.1 DOES NOT USE DIALYSATE OR REPLACEMENT FLUIDS FOR REMOVAL OF EXCESS FLUID FROM BLOODSTREAM
                    TABLE 21 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP (Page No. - 101)
    8.1 INTRODUCTION 
          TABLE 22 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY AGE GROUP, 2021–2028 (USD MILLION)
    8.2 ADULTS 
           8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
                    TABLE 23 MARKET FOR ADULTS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 PEDIATRICS & NEONATES 
           8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO SUPPORT MARKET GROWTH
                    TABLE 24 MARKET FOR PEDIATRICS & NEONATES, BY COUNTRY, 2021–2028 (USD MILLION)
9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER (Page No. - 105)
    9.1 INTRODUCTION 
          TABLE 25 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 HOSPITALS 
           9.2.1 FASTEST-GROWING END-USER SEGMENT
                    TABLE 26 MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 AMBULATORY CARE 
           9.3.1 REDUCED INPATIENT STAY TO SUPPORT MARKET GROWTH
                    TABLE 27 MARKET FOR AMBULATORY CARE, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 HOME CARE 
           9.4.1 RISING ADOPTION OF PORTABLE AND HOME-BASED DEVICES TO AID MARKET GROWTH
                    TABLE 28 MARKET FOR HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 29 MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION (Page No. - 111)
     10.1 INTRODUCTION 
             TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        FIGURE 35 NORTH AMERICA: MARKET SNAPSHOT
                        TABLE 31 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 32 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 33 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 34 NORTH AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 35 NORTH AMERICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 36 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Large number of AKI patients to drive market
                                      TABLE 37 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 38 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 39 US: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 40 US: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 41 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 High cost of CRRT to negatively impact market growth
                                      TABLE 42 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 43 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 44 CANADA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 45 CANADA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 46 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        TABLE 47 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 48 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 49 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 50 EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 51 EUROPE: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 52 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Largest market for continuous renal replacement therapy in Europe
                                      TABLE 53 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 54 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 55 GERMANY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 56 GERMANY: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 57 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Rising number of sepsis cases to support market growth
                                      TABLE 58 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 59 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 60 UK: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 61 UK: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 62 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Growing AKI patient population to propel market growth
                                      TABLE 63 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 64 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 65 FRANCE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 66 FRANCE: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 67 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Government initiatives to promote awareness of renal care to drive market
                                      TABLE 68 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 69 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 70 ITALY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 71 ITALY: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 72 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Favorable reimbursement scenario to favor market growth
                                      TABLE 73 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 74 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 75 SPAIN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 76 SPAIN: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 77 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 78 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 79 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 80 REST OF EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 81 REST OF EUROPE: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 82 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        FIGURE 36 ASIA PACIFIC: MARKET SNAPSHOT
                        TABLE 83 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 84 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 85 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 86 ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 87 ASIA PACIFIC: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 88 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Well-established medical infrastructure to support market growth
                                      TABLE 89 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 90 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 91 JAPAN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 92 JAPAN: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 93 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Increasing prevalence of ESRD and AKI to boost demand for CRRT
                                      TABLE 94 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 95 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 96 CHINA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 97 CHINA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 98 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Large patient population to support market growth
                                      TABLE 99 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 100 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 101 INDIA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 102 INDIA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 103 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 Government initiatives to increase adoption of CRRT
                                      TABLE 104 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 105 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 106 AUSTRALIA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 107 AUSTRALIA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 108 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.6 SOUTH KOREA
                        10.4.6.1 Increasing awareness through online education programs and events to aid market growth
                                      TABLE 109 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 110 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 111 SOUTH KOREA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 112 SOUTH KOREA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 113 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 114 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 115 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 116 REST OF ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 117 REST OF ASIA PACIFIC: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 118 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        TABLE 119 LATIN AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 120 LATIN AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 121 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 122 LATIN AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 123 LATIN AMERICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 124 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Rising incidence of AKI to drive market
                                      TABLE 125 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 126 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 127 BRAZIL: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 128 BRAZIL: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 129 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Large patient population to drive market
                                      TABLE 130 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 131 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 132 MEXICO: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 133 MEXICO: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 134 MEXICO: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.4 REST OF LATIN AMERICA
                        TABLE 135 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 136 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 137 REST OF LATIN AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 138 REST OF LATIN AMERICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 139 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN MARKET GROWTH
             10.6.2 MIDDLE EAST AND AFRICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        TABLE 140 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 141 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 142 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 143 MIDDLE EAST & AFRICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 144 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 166)
     11.1 OVERVIEW 
             FIGURE 37 GROWTH STRATEGIES ADOPTED BY KEY PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
     11.2 REVENUE SHARE ANALYSIS OF MARKET PLAYERS, 2018–2022 (USD MILLION) 
             FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
             FIGURE 39 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
             TABLE 145 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY: DEGREE OF COMPETITION
     11.3 COMPANY EVALUATION MATRIX 
             11.3.1 STARS
             11.3.2 EMERGING LEADERS
             11.3.3 PERVASIVE PLAYERS
             11.3.4 PARTICIPANTS
                        FIGURE 40 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY: COMPANY EVALUATION MATRIX, 2022
     11.4 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 
             11.4.1 PROGRESSIVE COMPANIES
             11.4.2 STARTING BLOCKS
             11.4.3 RESPONSIVE COMPANIES
             11.4.4 DYNAMIC COMPANIES
                        FIGURE 41 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
     11.5 FOOTPRINT ANALYSIS OF PLAYERS IN MARKET 
             TABLE 146 PRODUCT, REGIONAL, AND END-USER FOOTPRINT ANALYSIS OF PLAYERS IN MARKET
             TABLE 147 PRODUCT FOOTPRINT OF COMPANIES
             TABLE 148 END-USER FOOTPRINT OF COMPANIES
             TABLE 149 REGIONAL FOOTPRINT OF COMPANIES
     11.6 MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2019 TO AUGUST 2023) 
             TABLE 150 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
     11.7 MARKET: DEALS (JANUARY 2019 TO AUGUST 2023) 
             TABLE 151 KEY DEALS
     11.8 MARKET: OTHER DEVELOPMENTS (JANUARY 2019 TO AUGUST 2023) 
             TABLE 152 OTHER KEY DEVELOPMENTS
12 COMPANY PROFILES (Page No. - 180)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     12.1 MAJOR PLAYERS 
             12.1.1 BAXTER INTERNATIONAL, INC.
                        TABLE 153 BAXTER INTERNATIONAL, INC.: BUSINESS OVERVIEW
                        FIGURE 42 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 154 BAXTER INTERNATIONAL, INC.: PRODUCT OFFERINGS
             12.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
                        TABLE 155 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
                        FIGURE 43 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 156 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
             12.1.3 NIKKISO CO., LTD.
                        TABLE 157 NIKKISO CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 44 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 158 NIKKISO CO., LTD.: PRODUCT OFFERINGS
             12.1.4 B. BRAUN MELSUNGEN AG
                        TABLE 159 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                        FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
                        TABLE 160 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
             12.1.5 MEDTRONIC PLC
                        TABLE 161 MEDTRONIC PLC: BUSINESS OVERVIEW
                        FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
                        TABLE 162 MEDTRONIC PLC: PRODUCT OFFERINGS
             12.1.6 ASAHI KASEI CORPORATION
                        TABLE 163 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 164 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
             12.1.7 TORAY MEDICAL CO., LTD.
                        TABLE 165 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 48 TORAY MEDICAL CO., LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 166 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
             12.1.8 NIPRO CORPORATION
                        TABLE 167 NIPRO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 49 NIPRO CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 168 NIPRO CORPORATION: PRODUCT OFFERINGS
             12.1.9 INFOMED SA
                        TABLE 169 INFOMED SA: BUSINESS OVERVIEW
                        TABLE 170 INFOMED SA: PRODUCT OFFERINGS
             12.1.10 MEDICA SPA
                        TABLE 171 MEDICA SPA: BUSINESS OVERVIEW
                        TABLE 172 MEDICA SPA: PRODUCT OFFERINGS
             12.1.11 MEDITES PHARMA SPOL. S.R.O.
                        TABLE 173 MEDITES PHARMA SPOL. S.R.O.: BUSINESS OVERVIEW
                        TABLE 174 MEDITES PHARMA SPOL. S.R.O.: PRODUCT OFFERINGS
             12.1.12 MEDICAL COMPONENTS, INC.
                        TABLE 175 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
                        TABLE 176 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
             12.1.13 SWS HEMODIALYSIS CARE CO., LTD.
                        TABLE 177 SWS HEMODIALYSIS CARE CO., LTD.: BUSINESS OVERVIEW
                        TABLE 178 SWS HEMODIALYSIS CARE CO., LTD.: PRODUCT OFFERINGS
             12.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
                        TABLE 179 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
                        TABLE 180 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
             12.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
                        TABLE 181 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
                        TABLE 182 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
             12.1.16 KIMAL
                        TABLE 183 KIMAL: BUSINESS OVERVIEW
                        TABLE 184 KIMAL.: PRODUCT OFFERINGS
             12.1.17 JIANGXI SANXIN MEDTEC CO., LTD.
                        TABLE 185 JIANGXI SANXIAN MEDTECH CO., LTD.: BUSINESS OVERVIEW
                        TABLE 186 JIANGXI SANXIAN MEDTECH CO., LTD.: PRODUCT OFFERINGS
     12.2 OTHER PLAYERS 
             12.2.1 ALLMED MEDICAL PRODUCTS CO., LTD.
             12.2.2 DIALCO MEDICAL INC.
             12.2.3 BROWNDOVE HEALTHCARE PVT. LTD.
             12.2.4 STERIS PLC
             12.2.5 KURARAY MEDICAL PLC
             12.2.6 LIVANOVA PLC
             12.2.7 DIAVERUM DEUTSCHLAND GMBH
             12.2.8 SEMBCORP INDUSTRIES
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 226)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS